Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nivolumab (BMS-936558)

5 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCURO1687

    01/31/2017

    A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor in Patients with Advanced Clear Cell Renal Cell Carcinoma

    Treatment

    VICCMD15128

    01/16/2017

    A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

    Treatment

    VICCGI1655

    12/14/2016

    A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


    Print this page for your doctor